Investor Relations November 13, 2025 Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel Read More
Investor Relations November 5, 2025 Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia Read More
Investor Relations October 30, 2025 Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel Read More
Investor Relations October 21, 2025 Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies Read More
Investor Relations October 13, 2025 Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer’s and Traumatic Brain Injury Programs Read More
Investor Relations October 10, 2025 Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit Read More
